[Management of XXXX during corticosteroid therapy].

@entity1 @entity6 @entity228 @entity37005 @entity520 @entity134 @entity413
BACKGROUND: Corticosteroids are generally contraindicated in @entity6 @entity1 due to the risk of disrupting @entity413 control leading to acute decompensation. In some cases however, @entity228 therapy can be beneficial if given early with a well-controlled regimen. @entity413 disequilibrium after withdrawal can be anticipated with proper knowledge of the pharmacokinetics of the glucocorticoid used. FOR @entity1 WITH TYPE I DIABETES: Ketose @entity520 is a real risk in these @entity1 . Insulin dose must be increased and the administration scheme optimized. FOR @entity1 WITH TYPE II DIABETES: Whether oral drugs should be continued is a question of debate, excepting cases where the underlying disease might cause acute decompensation requiring insulin. Outside this situation, oral drugs can be continued at a higher dose if the fasting serum @entity413 is below 2 g/L. Finally, it is important to recognized @entity134 -induced @entity6 in order to initiate proper antidiabetic measures. FOR ALL @entity1 : The @entity413 curve is reproducible. Basically, the postprandial level rises, warranting repeated insulin injections. Rapid-release analogs and alpha-glucosidase inhibitors appear to be promising; @entity37005 affect insulin resistance.
